|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
DE102004009933A1
(de)
*
|
2004-02-26 |
2005-09-15 |
Merck Patent Gmbh |
Verwendung von Thiadiazolharnstoffderivaten
|
|
US7550499B2
(en)
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
AU2005245389A1
(en)
*
|
2004-05-12 |
2005-12-01 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
US7977345B2
(en)
*
|
2004-07-02 |
2011-07-12 |
Exelixis, Inc. |
c-MET modulators and method of use
|
|
CN101039933B
(zh)
*
|
2004-09-17 |
2012-06-06 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的二氨基三唑化合物
|
|
EP1809282B1
(en)
*
|
2004-10-18 |
2013-01-09 |
Amgen, Inc |
Thiadiazole compounds and methods of use
|
|
US7767687B2
(en)
*
|
2004-12-13 |
2010-08-03 |
Biogen Idec Ma Inc. |
Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors
|
|
WO2006078621A2
(en)
*
|
2005-01-19 |
2006-07-27 |
Bristol-Myers Squibb Company |
2-phenoxy-n- (1, 3 , 4-thiadizol-2-yl) pyridin-3-amine derivatives and related compounds as p2y1 receptor inhibitors for the treatment of thromboembolic disorders
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
DE602006017694D1
(de)
*
|
2005-06-27 |
2010-12-02 |
Bristol Myers Squibb Co |
C-verknüpfte zyklische antagonisten des p2y1-rezeptors mit eignung bei der behandlung thrombotischer leiden
|
|
ATE502924T1
(de)
|
2005-06-27 |
2011-04-15 |
Bristol Myers Squibb Co |
Lineare harnstoffmimetika-antagonisten des p2y1- rezeptors zur behandlung von thromboseleiden
|
|
TW200726764A
(en)
*
|
2005-06-27 |
2007-07-16 |
Bristol Myers Squibb Co |
N-linked heterocyclic antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
WO2007002634A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
JP2009510132A
(ja)
*
|
2005-10-05 |
2009-03-12 |
メルク フロスト カナダ リミテツド |
ロイコトリエン生合成の阻害剤としての置換キノリン
|
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
|
US20070213378A1
(en)
*
|
2006-03-10 |
2007-09-13 |
Lymphosign Inc. |
Compounds for modulating cell proliferation, compositions and methods related thereto
|
|
EP2079739A2
(en)
|
2006-10-04 |
2009-07-22 |
Pfizer Products Inc. |
Pyrido[4,3-d]pyrimidin-4(3h)-one derivatives as calcium receptor antagonists
|
|
US7960569B2
(en)
*
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
WO2008139845A1
(ja)
*
|
2007-04-24 |
2008-11-20 |
Daiichi Sankyo Company, Limited |
新規アミド誘導体
|
|
HUE030912T2
(en)
|
2008-02-15 |
2017-06-28 |
Rigel Pharmaceuticals Inc |
Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
US8063058B2
(en)
|
2008-04-16 |
2011-11-22 |
Portola Pharmaceuticals, Inc. |
Inhibitors of syk and JAK protein kinases
|
|
AU2009238590A1
(en)
|
2008-04-22 |
2009-10-29 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
US8466290B2
(en)
|
2008-07-10 |
2013-06-18 |
Pharma Ip General Incorporated Association |
STAT3 inhibitor containing quinolinecarboxamide derivative as active ingredient
|
|
MY159327A
(en)
*
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
US8361962B2
(en)
*
|
2009-07-27 |
2013-01-29 |
Roche Palo Alto Llc |
Tricyclic inhibitors of JAK
|
|
PL2520575T3
(pl)
|
2009-12-28 |
2017-05-31 |
General Incorporated Association Pharma Valley Project Supporting Organization |
Związek 1,3,4-oksadiazolo-2-karboksyamidowy
|
|
KR101483215B1
(ko)
*
|
2010-01-29 |
2015-01-16 |
한미약품 주식회사 |
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
|
|
JP5855095B2
(ja)
|
2010-06-07 |
2016-02-09 |
ノボメディックス, エルエルシーNovomedix, Llc |
フラニル化合物およびその使用
|
|
EP2397482A1
(en)
*
|
2010-06-15 |
2011-12-21 |
Almirall, S.A. |
Heteroaryl imidazolone derivatives as jak inhibitors
|
|
CN101891697B
(zh)
*
|
2010-07-02 |
2011-08-31 |
山东大学 |
含1，2，4-噁二唑杂环α，β-不饱和酮类化合物
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
MX363551B
(es)
|
2011-11-23 |
2019-03-27 |
Portola Pharmaceuticals Inc Star |
Compuestos derivados de pirazina como inhibidores de cinasa.
|
|
KR101328126B1
(ko)
*
|
2012-04-10 |
2013-11-08 |
연세대학교 원주산학협력단 |
신규한 옥사디아졸 유도체 및 이의 알레르기 질환의 예방, 개선 또는 치료적 용도
|
|
MX371331B
(es)
|
2012-04-24 |
2020-01-27 |
Vertex Pharma |
Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
|
|
CN103382206B
(zh)
*
|
2012-05-04 |
2016-09-28 |
上海恒瑞医药有限公司 |
喹啉或喹唑啉类衍生物、其制备方法及其在医药上的应用
|
|
WO2014013014A1
(en)
|
2012-07-18 |
2014-01-23 |
Fundació Privada Centre De Regulació Genòmica (Crg) |
Jak inhibitors for activation of epidermal stem cell populations
|
|
WO2014058921A2
(en)
|
2012-10-08 |
2014-04-17 |
Portola Pharmaceuticals, Inc. |
Substituted pyrimidinyl kinase inhibitors
|
|
JP6218848B2
(ja)
*
|
2012-11-20 |
2017-10-25 |
プロキナーゼ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
プロテインキナーゼ阻害剤としてのチオエーテル誘導体
|
|
CL2012003253A1
(es)
*
|
2012-11-22 |
2013-01-11 |
Univ Concepcion |
Compuestos derivados de 1,3,4-tiadiazol alquilamidas y de chalconas, antagonistas del receptor trpv-1; uso de los compuestos para tratar el dolor cronico.
|
|
ME03336B
(me)
|
2013-03-12 |
2019-10-20 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
JP6408569B2
(ja)
|
2013-10-17 |
2018-10-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
|
|
AU2014353006B2
(en)
|
2013-11-20 |
2019-04-04 |
Signalchem Life Sciences Corp. |
Quinazoline derivatives as TAM family kinase inhibitors
|
|
JP6269942B2
(ja)
*
|
2014-02-20 |
2018-01-31 |
国立研究開発法人理化学研究所 |
ｐ３８ＭＡＰキナーゼγおよび／またはδ阻害剤
|
|
KR102894264B1
(ko)
*
|
2015-03-10 |
2025-12-02 |
오리진 온콜로지 리미티드 |
면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
|
|
WO2018041989A1
(en)
|
2016-09-02 |
2018-03-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for diagnosing and treating refractory celiac disease type 2
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
WO2018160944A1
(en)
*
|
2017-03-03 |
2018-09-07 |
Progenra, Inc. |
Azole compounds as ubiquitin-specific protease usp7 inhibitors
|
|
CN108148058B
(zh)
*
|
2018-02-08 |
2021-03-16 |
中国人民解放军第四军医大学 |
一种4-(2-巯基噻二唑)取代的嘧啶衍生物其制备方法及应用
|
|
EA202192575A1
(ru)
|
2019-03-21 |
2022-01-14 |
Онксео |
Соединения dbait в сочетании с ингибиторами киназ для лечения рака
|
|
EP3947737A2
(en)
|
2019-04-02 |
2022-02-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods of predicting and preventing cancer in patients having premalignant lesions
|
|
EP3955920A1
(en)
|
2019-04-16 |
2022-02-23 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of jak inhibitors for the treatment of painful conditions involving nav1.7 channels
|
|
CN114761006A
(zh)
|
2019-11-08 |
2022-07-15 |
Inserm(法国国家健康医学研究院) |
对激酶抑制剂产生耐药性的癌症的治疗方法
|
|
WO2021148581A1
(en)
|
2020-01-22 |
2021-07-29 |
Onxeo |
Novel dbait molecule and its use
|
|
CN114380817B
(zh)
*
|
2020-10-21 |
2024-06-21 |
中国医学科学院药物研究所 |
苯并咪唑并2-氨基-1,3,4-噻二唑化合物及其制法和药物用途
|
|
CA3236877A1
(en)
*
|
2021-11-08 |
2023-05-11 |
Ventus Therapeutics U.S., Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2023222565A1
(en)
|
2022-05-16 |
2023-11-23 |
Institut National de la Santé et de la Recherche Médicale |
Methods for assessing the exhaustion of hematopoietic stems cells induced by chronic inflammation
|